Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Applicability of anti-neovascular therapy to drug-resistant tumor: Suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin
  1. Home
  2. Publications
  3. Applicability of anti-neovascular therapy to drug-resistant tumor: Suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin

Applicability of anti-neovascular therapy to drug-resistant tumor: Suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin

Authors:
  • KSK Shimizu
    K Shimizu
  • NON Oku
    N Oku

Publisher website
Google Scholar
  • 30 May 2005
    • journal article
    • Published by Elsevier in International Journal of Pharmaceutics
    • Vol. 296  (1-2) , 133-141
    • DOI:10.1016/j.ijpharm.2005.02.030
    • PMID:15885465
Abstract
No abstract available
Keywords
  • ANGIOGENESIS
  • DRUG DELIVERY SYSTEM
  • POLYETHYLENE GLYCOL
  • PEG
  • LIPOSOME
  • DSPC
  • PBS
  • FBS
  • ADM
  • ACTIVE TARGETING
  • DISTEAROYLPHOSPHATIDYLCHOLINE
  • FETAL BOVINE SERUM
  • ANTI-NEOVASCULAR THERAPY
  • VEGF
  • ADRIAMYCIN
  • VASCULAR ENDOTHELIAL GROWTH FACTOR
  • PHOSPHATE-BUFFERED SALINE
  • DRUG RESISTANCE
Cited by 24 articles
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.